Curing APL through PML/RARA degradation by As2O3.

@article{LallemandBreitenbach2012CuringAT,
  title={Curing APL through PML/RARA degradation by As2O3.},
  author={Val{\'e}rie Lallemand-Breitenbach and Jun Zhu and Zhu Chen and Hugues de Th{\'e}},
  journal={Trends in molecular medicine},
  year={2012},
  volume={18 1},
  pages={36-42}
}
Acute promyelocytic leukemia (APL) is a hematological malignancy driven by the PML/RARA oncogene. The prognosis for patients with APL was revolutionized by two treatments: retinoic acid (RA) and As(2)O(3) (arsenic trioxide). These were both shown a posteriori to target PML/RARA, explaining their exquisite specificity for APL. Arsenic, as a single agent, cures up to 70% of patients, whereas APL patients treated with the combination of RA and As(2)O(3) reach a stunning 90% cure rate. Recent… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…